Sibeprenlimab-szsi (Voyxact) for IgA Nephropathy
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.775 alerts
Get alerted when Policy CP.PHAR.775 changes without checking for updates manually.
Monitor payer policy activity
Policy governing prior authorization, medical necessity criteria, and coverage for Voyxact (sibeprenlimab-szsi) to reduce proteinuria in adults with primary IgA nephropathy for members of QualChoice lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Voyxact (sibeprenlimab-szsi)
Initial Therapy — Immunoglobulin A Nephropathy
Covered when ALL of the following are met:
Illinois HIM requests exempt from step therapy requirements per IL HB 5395
Continuation Therapy
Continued therapy covered when ALL of the following are met:
Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the requestor provides sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (e.g., CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or unless coverage is supported by the member's evidence of coverage documents.
For Medicaid members, when a state Medicaid coverage provision conflicts with the coverage provisions in this clinical policy, the state Medicaid provision takes precedence. Refer to the applicable state Medicaid manual for any specific coverage rules that apply to this medication.
Clinical Thresholds and Key Values
Provider Requirements, Prior Authorization, and Documentation
Prior authorization required — coverage only when criteria met
Prior authorization is required for Voyxact; therapy is considered medically necessary only when the policy’s specified initial or continued therapy criteria are met (see coverage criteria for diagnosis, proteinuria/eGFR thresholds, prior therapy requirements, and dosing limits).
- Therapy limits: 400 mg every 4 weeks and 1 prefilled syringe per 4 weeks.
Policy guides prior authorization and coverage determinations
This clinical policy is intended to guide medical necessity determinations and to assist in making coverage decisions and administering benefits; prior authorization requirements are governed by the Health Plan’s administrative procedures. It does not guarantee payment or alter plan terms.
Step therapy — required prior medication failures
Voyxact requests must document prior failure of a RAAS inhibitor for at least 12 weeks at a RAAS dose of ≥50% of the maximum labeled dose (unless contraindicated) and failure of an SGLT2 inhibitor at up to maximally indicated dosing; additionally, failure of Filspari or Vanrafia at up to maximally indicated doses is required unless contraindicated.
- RAAS failure: ≥12 weeks and RAAS dose ≥50% of max labeled dose.
- SGLT2 inhibitor failure: up to maximally indicated doses.
- Also requires failure of Filspari or Vanrafia at up to maximally indicated doses, unless contraindicated.
Step therapy note — no other step therapy requirements
No additional or alternative step therapy requirements are specified elsewhere in this policy segment beyond those listed for initial approval; Illinois HIM requests are exempt per IL HB 5395 where noted in the criteria.
- Illinois HIM exemption for step therapy effective 1/1/2026 (IL HB 5395).
Required documentation — submit clinical records and labs
Providers must submit supporting clinical documentation with the prior authorization request, such as office chart notes, laboratory results (e.g., UPCR, urine protein/day, eGFR), and other clinical information demonstrating that all approval criteria are met.
- Documentation should include biopsy-confirmed IgAN, nephrology consult/prescriber, age, proteinuria and eGFR values, prior medication trial details (duration and dosing), and response measures for continuation requests (e.g., reduction in UPCR or urine protein).
Submission must follow Health Plan administrative and legal requirements
When submitting requests, providers must follow applicable Health Plan-level administrative policies and procedures and comply with state and federal legal and regulatory requirements; the Health Plan’s effective dates and regulatory obligations take precedence where applicable.
Insufficient documentation or non‑FDA indications may lead to denial or request for more information
Requests that lack the required supporting documentation or that request coverage for non‑FDA indications without sufficient evidence per off‑label policies may be denied; submissions that conflict with plan terms, exclusions, or state/federal requirements may also be denied or require additional information.
- Incomplete documentation demonstrating criteria (e.g., biopsy, proteinuria, eGFR, prior therapy trials) may result in denial.
- Non‑FDA indications require sufficient evidence per off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) or evidence of coverage documents.
Coverage subject to plan documents, exclusions, and legal requirements
Coverage and administration of benefits are subject to the terms, conditions, exclusions, and limitations of the member’s coverage documents and applicable state and federal requirements; a favorable medical necessity determination does not override plan contract language.
Background on Voyxact and Indication
Voyxact (sibeprenlimab‑szsi) is an APRIL blocker that received accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression. Continued approval is contingent upon confirmatory trials because the long‑term effect on kidney function has not yet been established. Treatment and coverage decisions must follow the criteria in this policy, including specified proteinuria and renal function thresholds, and documentation requirements for efficacy and safety.
Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.